bullish

Resapp Health

ResApp’s Confirmatory Study Fails, Resulting in Pfizer’s Lower A$0.146 Offer

The revised SID provides no obvious way for Pfizer to pull its offer. At the last close of A$0.125, the gross spread to the unconfirmed data offer price of A$0.146 is 16.8%.

Event-Driven
373 Views, 21 Jun 2022 19:28
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top 5%
Arun George
IPOs and Catalysts/Events
Global Equity Research Ltd
Information TechnologyEquitiesEquity Capital MarketsEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • Merger Arb Mondays (18 Jul) - Link Admin, AOF, DTAC/True, Ramsay Health, ResApp, Infomedia
    18 Jul 2022
  • Merger Arb Mondays (04 Jul) - Link Admin, Ramsay, DTAC/True, Australian Unity Office Fund, Yashili
    04 Jul 2022
  • Merger Arb Mondays (27 Jun) - Ramsay Health, Link Admin, Link Net, True/DTAC, ResApp, Giordano
    27 Jun 2022
  • ResApp’s Confirmatory Study Fails, Resulting in Pfizer’s Lower A$0.146 Offer
    21 Jun 2022
  • ResApp Draws a Revised Binding Offer from Pfizer
    14 Jun 2022
x